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Increased Risk of Cutaneous and
Systemic Infections in Atopic Dermatitis—A
Cohort Study
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TO THE EDITOR
Atopic dermatitis (AD, also known as
atopic eczema or eczema), is charac-
terized by skin barrier and immuno-
logic dysfunction. Viral and bacterial
superinfection of cutaneous lesions,
including eczema herpeticum and
Staphylococcus aureus in patients with
severe disease is well documented
(Ong and Leung, 2016; Weidinger and
Novak, 2016). Whether the general
population of patients with AD has an
increased risk of these and other types
of infections because of an impaired
skin barrier and/or immunologic
dysfunction is unclear.
A recent meta-analysis of genome-
wide association studies identified mu-
tations in genes thought to play roles in
the regulation of innate and adaptive
immunity, in addition to established
barrier function susceptibility loci such
as filaggrin (Paternoster et al., 2015).
Investigations of skin physiology sug-
gest that differences in barrier function
are identifiable very early in infancy
and are highly predictive of the devel-
opment of AD (Kelleher et al., 2015).
We therefore hypothesized that in-
dividuals who develop AD are at
increased risk of infections because of
underlying genetically influenced im-
mune and barrier dysfunction. The
objective of our study was to determine
if there was an association between AD
and multiple common cutaneous and
noncutaneous infections.
We performed a cohort study using
The Health Improvement Network, a
medical records database that is
representative of the UK general pop-
ulation (Seminara et al., 2010). Ethics
approval for this study was obtained
from The Health Improvement
Network Scientific Review Committee
and the University of Pennsylvania
Institutional Review Board. We
included 3,112,617 individuals regis-
tered before age 18 years who were
followed for a mean of 13.7 years (95%
confidence interval ¼ 13.6, 13.7). We
identified subjects with AD based on
the presence of at least one of any of the
following diagnostic codes on two
different visits, as is common practice in
studies of chronic conditions using
electronic health data (Herrett et al.,
2010): atopic dermatitis and related
conditions (M11.00), atopic dermatitis/
AD (M111.00), and atopic dermatitis
not otherwise specified (M11z.00). The
prevalence of AD was 14.4% (95%
confidence interval ¼ 14.4e14.4).
We examined the prevalence of
multiple common cutaneous and non-
cutaneous infections (warts, dermato-
phyte infection, impetigo, molluscum
contagiosum, otitis media, pneumonia,
and streptococcal throat infection;
codes available in Supplementary
Table S1 online). We found that all of
the infectious illnesses we had deter-
mined to test a priori were more prev-
alent in those with AD. Using
multilevel mixed-effects logistic
regression, we examined the odds of
each infectious outcome at any time
point and found that the strength of
association for cutaneous infections
varied from a 55% increased odds of
impetigo to a 3-fold increased odds of
Abbreviation: AD, atopic dermatitis
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molluscum contagiosum after adjusting
for sex, age, time of observation, and
practice. Associations with non-
cutaneous infections varied from 27%
increased odds of streptococcal throat
infections to a 2-fold increase in otitis
media (Table 1).
We performed sensitivity analyses
exploring the definition of AD. When
we estimated the association with a
longer list of less-specific dermatitis
codes (see Supplementary Table S1),
we found that most associations were
diminished. When we estimated the
association with a more narrow desig-
nation, AD plus asthma or seasonal
rhinitis, the magnitude of most of the
associations increased. This highlighted
a potential link between underlying
immune dysfunction in atopic disease
and increased susceptibility to
infection.
Prior publications have found higher
rates of infections among patients with
AD, but most are from clinical pop-
ulations, and therefore are likely to
represent the more severe end of the
AD spectrum (Beck et al., 2009; Peng
et al., 2007), or are based on patient
self-report, and therefore may be
subject to recall and misclassification
biases (Silverberg and Silverberg, 2014;
Strom and Silverberg, 2016). Indirect
evidence also comes from multiple
studies that show an association be-
tween antibiotic use in early life and
AD (Schmitt and Weidinger, 2014;
Tsakok et al., 2013).
Strengths of this study include
physician-confirmed diagnoses and a
large longitudinal population-based
sample. A number of potential limita-
tions also warrant discussion. Our
finding of an increased risk of cuta-
neous infections could be due to
ascertainment bias (i.e., individuals
with AD are more likely to have their
skin checked and have skin conditions
diagnosed). Although it is less likely
that AD patients would have differential
recording of systemic infections such as
otitis or pneumonia, there may be a
lower threshold for diagnosis or
treatment of upper respiratory in-
fections among patients with comorbid
asthma, given the concern for asthma
exacerbations with viral illness. More-
over, patients with chronic conditions
like AD may be more likely to seek
care. Nonetheless, our findings are
important from a resource planning
perspective; additional research is
needed to understand the causal rela-
tionship between AD and infections.
Finally, because AD can have a het-
erogeneous presentation, diagnosis
may occasionally require specialist
care, and we did not have access to
dermatologist records. However, we
believe our reliance on general practice
physician records is reasonable in this
context given that the vast majority
(97%) of AD in the UK is treated in
primary care (Emerson et al., 1998;
Schofield, 2009).
We did not have detailed data about
disease severity, flares, or timing of
treatment use. Future studies exam-
ining whether there is a temporal as-
sociation between these factors and
infections could provide clinically
useful prognostic information. Addi-
tionally, information on the timing of
treatment use relative to infections
could help establish whether specific
treatment improves barrier function
and reduces infection risk or whether
immunosuppressive treatment in-
creases infection risk. Because we
studied the risk of infection at any time
Table 1. Prevalence and risk of infectious outcomes among those with AD compared with those without AD
Variable
Descriptive Statistics
Primary Analysis:
Risk of Infectious Outcome Ever
Sensitivity Analysis:
Risk of Infectious Outcome
Ever Using Different Exposure
Definitions
Overall Prevalence
(n [ 3,112,617)
Prevalence among
Those with AD
(n [ 448,311) Crude Adjusted1
Dermatitis
(n [ 632,707)
Crude
AD and Asthma
and/or Rhinitis
(n [ 162,116)
Crude
n %
(95% CI)
n %
(95% CI)
OR
(95% CI)
OR
(95% CI)
OR
(95% CI)
OR
(95% CI)
Cutaneous infections
Cutaneous warts 285,011
9.12 (9.12e9.19)
72,681
16.21 (16.10e16.32)
2.23 (2.21e2.25) 1.98 (1.96e2.00) 1.50 (1.48e1.53) 2.91 (2.87e2.95)
Dermatophyte infection 24,693
0.79 (0.78e0.80)
7,899
1.76 (1.72e1.80)
2.83 (2.75e2.90) 2.54 (2.47e2.61) 2.14 (2.02e2.26) 3.56 (3.44e3.69)
Herpes simplex virus 65,027
2.09 (1.07e2.10)
18,461
4.11 (4.06e4.18)
2.41 (2.37e2.46) 2.08 (2.04e2.12) 1.81 (1.75e1.88) 3.26 (3.19e3.34)
Impetigo 21,467
0.69 (0.68e0.70)
7,899
1.76 (1.72e1.80)
3.50 (3.41e3.60) 1.55 (1.47e1.64) 2.06 (1.96e2.18) 3.82 (3.69e3.96)
Molluscum contagiosum 118,325
3.80 (3.78e3.82)
43,997
9.81 (9.73e9.90)
3.79 (3.74e3.84) 3.11 (3.07e3.14) 1.82 (1.78e1.86) 3.50 (3.44e3.56)
Systemic infections
Otitis media 744,512
23.92 (23.87e23.97)
192,112
42.85 (42.71e43.00)
2.87 (2.85e2.88) 2.24 (2.22e2.25) 1.74 (1.72e1.76) 3.43 (3.40e3.47)
Pneumonia 69,880
2.24 (2.22e2.26)
17,087
3.81 (3.76e3.87)
1.96 (1.93e1.99) 1.27 (1.23e1.31) 1.48 (1.44e1.53) 2.76 (2.69e2.82)
Streptococcal throat
infection
18,271
0.59 (0.58e0.59)
4,558
1.02 (0.99e1.05)
1.98 (1.92e2.05) 1.34 (1.26e1.42) 1.38 (1.30e1.46) 2.72 (2.60e2.84)
Abbreviations: CI, confidence interval; OR, odds ratio.
1Adjusted for age at registration, sex, and time under observation. Physician practice included as a random effect in the model.
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point (including before AD diagnosis
and treatment), our results are unlikely
to be confounded by immunosuppres-
sive treatment use for AD. As noted,
multiple studies have shown an asso-
ciation between AD and early-life
antibiotic exposure, which provides
support for our hypothesis that patients
with AD are at an increased risk of
infection even before AD diagnosis,
and/or could indicate an effect of
antibiotics on the development of AD
(Schmitt and Weidinger, 2014; Tsakok
et al., 2013). Additional work is
needed to determine whether antibiotic
treatment plays a causal role in the
development of AD.
In summary, we found increased risks
of all infectious outcomes examined,
which include both cutaneous
and noncutaneous infections caused
by bacteria, viruses, and fungi. This
observation raises numerous questions
about the nature of immunological
defects in AD. One study found that
subjects with AD in whom eczema
herpeticum develops have more severe
T helper type 2 cell-polarized disease,
more atopic comorbidities, and more
cutaneous infections (Beck et al.,
2009). Our study adds epidemiologic
evidence suggesting that AD patients
may additionally be at risk of non-
cutaneous infections. A significant
body of functional and genotype/
phenotype data has been developed for
filaggrin (McAleer and Irvine, 2013),
and there is a need for similar work
linking immunological defects to clin-
ical phenotypes.
Determining if individuals with AD
are at increased risk of infections is
important to guide the development of
screening and prevention programs to
reduce the morbidity associated with
AD. Moreover, a baseline understanding
of infectious risk is particularly important
in the context of the introduction of the
many new biologic therapies now in the
pipeline for AD.
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